Crescent Capital BDC (CCAP) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
Net investment income (NII) for Q4 2024 was $0.55 per share, down from $0.64 in Q3, and net income per share was $0.27; NAV per share was stable at $19.98 at year-end 2024.
Portfolio remains highly diversified across 185 companies in 20 industries, with 90% in first-lien or unitranche loans and 97% at floating rates.
Regular Q1 2025 dividend declared at $0.42 per share, with three $0.05 special dividends announced for 2025.
Total assets at year-end were $1.66 billion, with net assets of $741 million.
Non-accruals were 0.9% of fair value and 1.7% of cost, below industry average.
Financial highlights
Q4 2024 total investment income was $46.4 million, down from $51.6 million in Q3, mainly due to lower benchmark rates.
Net realized and unrealized losses on investments per share were ($0.28) in Q4 2024.
Net deployment in Q4 was $21 million, with $127 million gross deployment and $106 million in exits, sales, and repayments.
Full-year 2024 investment income rose to $197.4 million from $184.1 million in 2023.
Debt-to-equity ratio increased to 1.19x at year-end.
Outlook and guidance
Anticipates increased LBO volumes and deal flow in 2025, supported by favorable economic and regulatory conditions and private equity dry powder.
Expects interest income to decline further in Q1 2025 due to the full impact of Q4 rate cuts.
Portfolio strategy remains conservative, emphasizing first lien loans and defensive positioning.
Regular and special dividends announced for 2025, with the supplemental distribution framework in effect.
Latest events from Crescent Capital BDC
- Q4 net investment income covered the dividend, with NAV at $19.10 and a defensively positioned portfolio.CCAP
Q4 202526 Feb 2026 - Q2 2024 NII reached $0.59/share, NAV $20.30, with strong liquidity and stable credit.CCAP
Q2 20241 Feb 2026 - Q3 net investment income rose to $0.64 per share, with strong liquidity and low non-accruals.CCAP
Q3 202414 Jan 2026 - Board urges ratification of Ernst & Young LLP as auditor, with 2024 fees totaling $841,150.CCAP
Proxy Filing2 Dec 2025 - Director elections and auditor ratification headline the 2025 annual meeting agenda.CCAP
Proxy Filing2 Dec 2025 - Stockholders will vote virtually on director elections and auditor ratification, with strong board oversight.CCAP
Proxy Filing2 Dec 2025 - Net investment income and NAV per share fell, but dividends and portfolio quality remain strong.CCAP
Q1 202526 Nov 2025 - Q2 2025 delivered strong income, stable NAV, and a $20M share repurchase program.CCAP
Q2 202523 Nov 2025 - Net investment income steady at $0.46 per share; NAV and net income per share declined.CCAP
Q3 202517 Nov 2025